Skip to main content

Reshaping undesired Inflammation in challenged Tissue Homeostasis by Next-Generation regulatory T cell (Treg) Approaches – from Advanced Technology Developments to First-in-Human Trials

Objective

Adoptive transfer of regulatory T cells (Treg) is a promising new therapeutic option to reshape undesired intra-tissue immune imbalance in immune-related disease entities. It supports long-term function of allografts and use of Advanced Therapy Medicinal Products (ATMP) by overcoming the challenge of unwanted immune reaction by the recipient of the ATMP. Therefore, adoptive Treg therapy is a potential game changer in health care, particularly in immune diseases, organ & hematopoietic stem cell (HSC) transplantation, and regenerative medicine, including gene therapy.
Based on the Triple-T concept - Transdisciplinarity, Technology, Translation - the major goal of RESHAPE is to transform the treatment of patients suffering from undesired immunity/inflammation, who presently have limited curative treatment options, by applying novel Treg approaches that overcome the limitations of 1st generation Treg product developments.
Members of the consortium, with academic & biotech backgrounds, are pioneers in the development of Treg therapy from basic science to very recent encouraging First-In-Human (FIH) clinical trials of the 1st generation Treg products. They have a longtrack record of collaboration, including in EC-funded projects. The first clinical trials were performed to combat organ transplant rejection and Graft-versus-Host-Disease. However, promising preclinical studies offer a broad application field of Treg therapy beyond allotransplantation.
Based on our preclinical & clinical data, we have identified several opportunities for improving Treg therapy, such as enhanced antigen specificity & functional stability, and recipient conditioning, that will be addressed by RESHAPE. The next-generation Treg products, developed by advanced technologies including CRISPR/Cas9, will be tested on platforms applying new methods for cell characteristics in both in vivo /in vitro models, and finally proven in FIH-clinical trials accompanied by biomarker and health economic studies

Call for proposal

H2020-SC1-2018-Single-Stage-RTD
See other projects for this call

Coordinator

CHARITE - UNIVERSITAETSMEDIZIN BERLIN
Address
Chariteplatz 1
10117 Berlin
Germany
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 4 218 425

Participants (9)

MEDIZINISCHE HOCHSCHULE HANNOVER
Germany
EU contribution
€ 1 714 942,50
Address
Carl-neuberg-strasse 1
30625 Hannover
Activity type
Higher or Secondary Education Establishments
CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES

Participation ended

France
EU contribution
€ 5 000
Address
Allee De L'ile Gloriette 5
44093 Nantes
Activity type
Higher or Secondary Education Establishments
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
United Kingdom
EU contribution
€ 2 150 425
Address
Wellington Square University Offices
OX1 2JD Oxford
Activity type
Higher or Secondary Education Establishments
NATURWISSENSCHAFTLICHES UND MEDIZINISCHES INSTITUT AN DER UNIVERSITAET TUEBINGEN
Germany
EU contribution
€ 521 375
Address
Markwiesenstrasse 55
72770 Reutlingen
Activity type
Research Organisations
CELL THERAPY CATAPULT LIMITED
United Kingdom
EU contribution
€ 1 036 660
Address
12Th Floor Tower Wing Guy's Hospital Great Maze Pond
SE1 9RT London
Activity type
Research Organisations
TISSUSE GMBH
Germany
EU contribution
€ 1 044 125
Address
Oudenarder Strasse 16
13347 Berlin
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
TXCELL

Participation ended

France
EU contribution
€ 0
Address
Les Cardoulines Allee De La Nertiere Sophia Antipolis
06560 Valbonne
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
INNOVATION ACTA S.R.L.
Italy
EU contribution
€ 426 100
Address
Via D.a. Azuni, 9
00196 Roma
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
UNIVERSITE DE NANTES
France
EU contribution
€ 2 020 343,75
Address
Quai De Tourville 1
44035 Nantes Cedex 1
Activity type
Higher or Secondary Education Establishments